Skip to content

Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over

Evaluation of the Impact of Locoregional Treatment of Soft Tissue Sarcoma on the Functional Status of Patients Aged 70 Years and Over

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03077178
Acronym
SARCOLD
Enrollment
25
Registered
2017-03-10
Start date
2017-11-30
Completion date
2026-03-01
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft Tissue Sarcoma Adult

Keywords

Soft Tissue Sarcoma, Surgery, Functional Impact, Elderly Patient, Geriatrics

Brief summary

In order to describe functional impact of surgery in elderly patients treated for lower-limb soft-tissue sarcoma, the investigators set up this project which aims to identify prognostic factors among geriatric and functional assessment.

Detailed description

This is a prospective cohort including 100 patients \> 70 year-old treated by surgery for lower-limb soft-tissue sarcoma. Data on clinical and geriatric characteristics of the patient as well as functional and quality of life assessment will be collected among patient participation (3 years). Primary endpoint is to describe evaluation of the Impact of Locoregional Treatment of Soft Tissue Sarcoma on the Functional Status.

Interventions

PROCEDUREGeriatric assessment

Geriatric assessment, questionnaire assessment

Sponsors

Institut Bergonié
Lead SponsorOTHER
Ministry of Health, France
CollaboratorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Aged more than 70 years, 2. Soft tissue sarcoma histologically proven, 3. Sarcoma of the soft tissues of the lower limbs, 4. Operable disease (first-line treatment or neo-adjuvant therapy), 5. ECOG, Performance Status ≤ 2, 6. Decision of surgery validated in Multidisciplinary Consultation Meeting, 7. Reports of the non-opposition documented in the patient file before any procedure specific to the study, 8. Affiliation to system of Social Security (accordance with article L1121-11 of the Code of Public Health).

Exclusion criteria

1. Metastatic disease from the onset or relapse 2. Participation in another study involving a similar geriatric assessment. 3. Geographic, familial, social, psychological or psychiatric factors that make the patient incapable of undergoing the study's follow-up and procedures. 4. Persons deprived of liberty or placed under judicial protection

Design outcomes

Primary

MeasureTime frameDescription
Change in Physical functioning assessmentChange from baseline until 36 months after surgeryQuality of life questionnaire QLQ-C30

Secondary

MeasureTime frameDescription
Functional status assessment (TESS)Change from baseline until 36 months after surgeryToronto Extremity salvage score (TESS) Scale
Functional status assessment (MST)Change from baseline until 36 months after surgeryMuskuloskeletal Tumor Society (MST) scale
Quality of life assessment QLQ-C30Change from baseline until 36 months after surgeryQuality of life questionnaire QLQ-C30
Quality of life assessment QLQ-EDL-14Change from baseline until 36 months after surgeryQuality of life questionnaire QLQ-EDL-14
Geriatric parameters assessment - G8baselineG8 (onco-geratic screening score)
Surgical complicationsChange from Day 0 until 12 months after surgeryclassification Clavien Dindo
OSChange from Day 0 until 36 months after surgeryOverall Survival

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026